Showing 4611-4620 of 5152 results for "".
- ASDS Honors Dr. Ian Maher for Outstanding Servicehttps://practicaldermatology.com/news/asds-honors-dr-ian-maher-for-outstanding-service/2458764/The American Society for Dermatologic Surgery (ASDS) last month presented Ian A. Maher, MD, of St. Louis with the ASDS Award for Outstanding Service. The award is given annually to one member who has volunteered his or her time for multiple Society projects or initiatives. In an effort to recogni
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Strathspey Crown Appointments Murthy Simhambhatla, PhD, as Senior Partnerhttps://practicaldermatology.com/news/strathspey-crown-appointments-murthy-simhambhatla-phd-as-senior-partner/2458776/Strathspey Crown Holdings LLC announced the appointment of Murthy Simhambhatla, PhD as a Senior Partner of the firm. Dr. Simhambhatla has more than 20 years of experience in bioscience and has built a successful track record in the healthcare industry. Dr. Simhambhatla was
- New Rosacea Research Findings Presented During SID Annual Meetinghttps://practicaldermatology.com/news/new-rosacea-research-findings-presented-during-sid-annual-meeting/2458777/Medical scientists reviewed research on the microbiome, genetics and pathophysiology of rosacea and presented results of new studies funded by the National Rosacea Society (NRS) during its research workshop at the Society for Investigative Dermatology annual meeting. “Research suppo
- Valeant Issues Updated Financial Guidancehttps://practicaldermatology.com/news/valeant-issues-updated-financial-guidance/2458779/Valeant Pharmaceuticals International, Inc. announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016. "We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and ou
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor